GSK3A and Patent ductus arteriosus: The preferential activity of GSK3α over GSK3β in cancer cells has also been reported in pancreatic ductal adenocarcinoma (PDA), in which GSK3α, but not GSK3β, promotes activation of the canonical and non-canonical NF-κB pathways to promote cell viability and apoptosis resistance [44,45].